Ratings Indoco Remedies Limited Bombay S.E.

Equities

INDOCO

INE873D01024

Market Closed - Bombay S.E. Other stock markets 11:00:47 17/05/2024 BST			5-day change	1st Jan Change
319.7 ^INR	-0.05%		0.00%	-18.91%

05-16	Indoco Remedies Gets Zero Observations from US FDA for Navi Mumbai, India Plant, IAS Division	MT
05-16	Transcript : Indoco Remedies Limited, Q4 2024 Earnings Call, May 16, 2024

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The firm trades with high earnings multiples: 27.21 times its 2024 earnings per share.
The company is not the most generous with respect to shareholders' compensation.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past twelve months, analysts' opinions have been revised negatively.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
INDOCO REMEDIES LIMITED	-18.91%	355M	C+
ELI LILLY AND COMPANY	+32.36%	694B	C+
NOVO NORDISK A/S	+29.84%	593B	B
JOHNSON & JOHNSON	-1.60%	371B	C+
MERCK & CO., INC.	+20.07%	331B	B-
ABBVIE INC.	+6.04%	290B	C+
ASTRAZENECA PLC	+14.53%	239B	B+
ROCHE HOLDING AG	-3.19%	209B	A+
NOVARTIS AG	+10.09%	209B	B-
AMGEN INC.	+9.27%	169B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes